Significant Association of Matrix Metalloproteinase-9 Polymorphisms With Triple Negative Breast Cancer Risk.

IF 2.6 4区医学 Q2 GENETICS & HEREDITY

Cancer Genomics & Proteomics Pub Date : 2025-03-01 DOI:10.21873/cgp.20500

Chih-Chiang Hung, Yun-Chi Wang, Hou-Yu Shih, Chia-Hua Liu, Jie-Long He, Jaw-Chyun Chen, Wen-Shin Chang, Chen-Hsien Su, DA-Tian Bau, Chia-Wen Tsai

{"title":"Significant Association of Matrix Metalloproteinase-9 Polymorphisms With Triple Negative Breast Cancer Risk.","authors":"Chih-Chiang Hung, Yun-Chi Wang, Hou-Yu Shih, Chia-Hua Liu, Jie-Long He, Jaw-Chyun Chen, Wen-Shin Chang, Chen-Hsien Su, DA-Tian Bau, Chia-Wen Tsai","doi":"10.21873/cgp.20500","DOIUrl":null,"url":null,"abstract":"Background/aim: Matrix metalloproteinase-9 (MMP-9) has been associated with the development and progression of breast cancer (BCa). However, the relationship between MMP-9 genetic variants and BCa susceptibility remains contentious and inconclusive. This study aimed to evaluate the association of MMP-9 rs3918242 promoter polymorphisms with BCa, with a particular focus on the risk of triple-negative breast cancer (TNBC).Materials and methods: A case-control study was conducted involving 1,232 BCa patients and 1,232 healthy controls. The MMP-9 rs3918242 genotypes were determined using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis.Results: The genotype distribution of MMP-9 rs3918242 among the control group adhered to Hardy-Weinberg equilibrium (p=0.3265). No statistically significant differences were observed in the genotype frequencies between BCa cases and controls (p for trend=0.2555). Although the homozygous variant genotype (TT) showed a potential risk-increasing effect, this was not statistically significant [odds ratio (OR)=1.43, 95% confidence interval (CI)=0.88-2.36, p=0.1869]. Similarly, allele frequency analysis indicated no significant association between the variant T allele and overall BCa risk (OR=1.13, 95%CI=0.97-1.33, p=0.1265). Additionally, no interaction was detected between MMP-9 rs3918242 genotypes and the age of BCa onset (both p>0.05). Notably, the TT genotype of MMP-9 rs3918242 was significantly associated with an increased risk of TNBC (OR=2.49, 95%CI=1.32-4.72, p=0.0072).Conclusion: The MMP-9 rs3918242 TT genotype may serve as a potential predictive biomarker for TNBC in the Taiwanese population.","PeriodicalId":9516,"journal":{"name":"Cancer Genomics & Proteomics","volume":"22 2","pages":"258-270"},"PeriodicalIF":2.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880922/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Genomics & Proteomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/cgp.20500","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Matrix metalloproteinase-9 (MMP-9) has been associated with the development and progression of breast cancer (BCa). However, the relationship between MMP-9 genetic variants and BCa susceptibility remains contentious and inconclusive. This study aimed to evaluate the association of MMP-9 rs3918242 promoter polymorphisms with BCa, with a particular focus on the risk of triple-negative breast cancer (TNBC).

Materials and methods: A case-control study was conducted involving 1,232 BCa patients and 1,232 healthy controls. The MMP-9 rs3918242 genotypes were determined using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis.

Results: The genotype distribution of MMP-9 rs3918242 among the control group adhered to Hardy-Weinberg equilibrium (p=0.3265). No statistically significant differences were observed in the genotype frequencies between BCa cases and controls (p for trend=0.2555). Although the homozygous variant genotype (TT) showed a potential risk-increasing effect, this was not statistically significant [odds ratio (OR)=1.43, 95% confidence interval (CI)=0.88-2.36, p=0.1869]. Similarly, allele frequency analysis indicated no significant association between the variant T allele and overall BCa risk (OR=1.13, 95%CI=0.97-1.33, p=0.1265). Additionally, no interaction was detected between MMP-9 rs3918242 genotypes and the age of BCa onset (both p>0.05). Notably, the TT genotype of MMP-9 rs3918242 was significantly associated with an increased risk of TNBC (OR=2.49, 95%CI=1.32-4.72, p=0.0072).

Conclusion: The MMP-9 rs3918242 TT genotype may serve as a potential predictive biomarker for TNBC in the Taiwanese population.

查看原文本刊更多论文

基质金属蛋白酶-9多态性与三阴性乳腺癌风险的显著关联

背景/目的：基质金属蛋白酶-9 （Matrix metalloproteinase-9, MMP-9）与乳腺癌（BCa）的发生发展有关。然而，MMP-9基因变异与BCa易感性之间的关系仍然存在争议和不确定性。本研究旨在评估MMP-9 rs3918242启动子多态性与BCa的关系，特别关注三阴性乳腺癌（TNBC）的风险。材料与方法：采用病例对照研究，纳入1232例BCa患者和1232例健康对照。采用聚合酶链反应-限制性片段长度多态性（PCR-RFLP）分析MMP-9 rs3918242基因型。结果：MMP-9 rs3918242在对照组中的基因型分布符合Hardy-Weinberg平衡（p=0.3265）。BCa病例与对照组基因型频率差异无统计学意义（趋势p =0.2555）。虽然纯合变异基因型（TT）显示出潜在的风险增加效应，但这没有统计学意义[优势比(OR)=1.43, 95%可信区间(CI)=0.88-2.36, p=0.1869]。同样，等位基因频率分析显示，变异T等位基因与总体BCa风险之间无显著相关性（OR=1.13, 95%CI=0.97-1.33, p=0.1265）。此外，MMP-9 rs3918242基因型与BCa发病年龄之间没有相互作用（p < 0.05）。值得注意的是，MMP-9 rs3918242的TT基因型与TNBC风险增加显著相关（OR=2.49, 95%CI=1.32-4.72, p=0.0072）。结论：MMP-9 rs3918242 TT基因型可作为台湾人群TNBC的潜在预测生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Genomics & Proteomics ONCOLOGY-GENETICS & HEREDITY

CiteScore

5.00

自引率

8.00%

发文量

期刊介绍： Cancer Genomics & Proteomics (CGP) is an international peer-reviewed journal designed to publish rapidly high quality articles and reviews on the application of genomic and proteomic technology to basic, experimental and clinical cancer research. In this site you may find information concerning the editorial board, editorial policy, issue contents, subscriptions, submission of manuscripts and advertising. The first issue of CGP circulated in January 2004. Cancer Genomics & Proteomics is a journal of the International Institute of Anticancer Research. From January 2013 CGP is converted to an online-only open access journal. Cancer Genomics & Proteomics supports (a) the aims and the research projects of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.